Wednesday 11 November 2026 Export VIR’s income statement to Excel — free account

Vir Biotechnology, Inc.

VIR

Vir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.

Revenue: −178.3%
EPS: +51.4%
Free cash flow: +36.8%

Quarter to September 2026, against a year earlier

Dividend growth 3 yrs

13.12 0.03 −0.23%

Follow VIR

Alert me

Market cap: $2.3B
P/E: n/m
Fwd P/E: n/m
Dividend yield: —
F-score: 4/9
ROIC: −30.3%
Net debt / EBITDA: 1.0×
Dividend safety: n/a

Overview

Vir Biotechnology, Inc. (VIR) P/S ratio

Alert me on P/S ratio

As of 11 November 2026, Vir Biotechnology, Inc. (VIR) trades at a P/S ratio of 7.3×. Over the past ten years it has ranged from 0.0× (January 2018) to 511× (June 2020); the current reading is higher than 28% of that period. That is below the Biotechnology industry median of 9.6× and above the Healthcare sector median of 3.6×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/VIR/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Vir Biotechnology, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/VIR/metrics/ps-ratio">Vir Biotechnology, Inc. (VIR) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	12.2×	(9.59%)
FY2024	13.5×	(17.61%)
FY2023	16.4×	699.81%
FY2022	2.0×	(58.80%)
FY2021	5.0×	(88.12%)
FY2020	41.8×	(11.45%)
FY2019	47.2×	220.39%
FY2018	14.7×	—
FY2017	0.0×	—

Period	P/S ratio	Change
Sep 2026	6.3×	10.89%
Jun 2026	5.6×	(72.04%)
Mar 2026	20.2×	65.46%
Dec 2025	12.2×	(74.11%)
28 more quarters	Free account

Against its own ten years

Low 0.0× High 511×

Ten-year median 15.7×

Current reading's percentile 27

Company	P/S ratio
TRAX First Tracks Biotherapeutics, Inc. compare	n/m
REPL Replimune Group, Inc. compare	n/m
BHVN Biohaven Ltd. compare	2.3×
VIR Vir Biotechnology, Inc.	7.3×
LKFT Lakefront Biotherapeutics - Sponsored ADR compare	7.8×
ZYME Zymeworks Inc. compare	7.8×
RXRX Recursion Pharmaceuticals, Inc. compare	28.4×
NAMS NewAmsterdam Pharma Company N.V. compare	98.7×
IMNM Immunome, Inc. compare	172×
Biotechnology industry median	9.6×
Healthcare sector median	3.6×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Vir Biotechnology, Inc. (VIR) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on VIR

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on VIR

Stockrow Weekly